Journal of Clinical Pharmacy and Therapeutics 2002: Vol 27 Index

7 Pages·2002·1.4 MB·English

Journal of Clinical Pharmacy and Therapeutics (2002) 27, 475-478
AUTHOR INDEX
Abebe, W. Herbal medication: potential for adverse Chow, A.T. see Chien, S.-C.
interactions with analgesic drugs, 391 Chowdhary, S. see Routledge, H.C.
Akhondzadeh, S., Mojtahedzadeh, V., Mirsepassi, G.-R., Ciaccia, L.M. see Schock Citver, A.
Moin, M., Amini-Nooshabadi, H. & Kamalipour, A. Ciccolini, J. see Monjanel-Mouterde, S.
Diazoxide in the treatment of schizophrenia: novel Codd, E.E. see Tao, Q.
application of potassium channel openers in the Colwill, S. see Ashworth, M.
treatment of schizophrenia, 453 Coogan, T.P. see Tao, Q.
Al Balushi, K. see Hanssens, Y. Cottrell, N. see Green, B.
Al Hashar, A. see Hanssens, Y. Cunningham, F. see Ren, X.S.
Al-Zakwani, I. see Hanssens, Y. Czock, D. see Uhl, A.
Amini-Nooshabadi, H. see Akhondzadeh, S.
Anderson, S. see Whitefield, M. D’Emden, M. see Green, B.
Armstrong, D. see Ashworth, M. Deleu, D. see Hanssens, Y.
Arsene, M., Favetta, P., Favier, B. & Bureau, J. Compar- Demoré, B., Vigneron, J., Perrin, A., Hoffman, M.A. &
ison of ceftazidime degradation in glass bottles and Hoffman, M. Leaching of diethylhexyl phthalate from
plastic bags under various conditions, 205 polyvinyl chloride bags into intravenous etoposide
Ashworth, M., Armstrong, D., Lloyd, D. & Colwill, S. The solution, 139
effects on GP prescribing of joining a commissioning Desai-Krieger, D. see Tao, Q.
group, 221 Dey, C.S. see Jayanarayan, K.G.
Ashworth, M., Golding, S. & Majeed, A. Prescribing Dickinson, J.A. see Wun, Y.T.
indicators and their use by primary care groups to Ding, B., Bertilsson, L. & Wahlestedt, C. The single
influence prescribing, 197 nucleotide polymorphism T1128C in the signal peptide
Ashworth, M. Re: GPs’ views on computerized drug of neuropeptide Y (NPY) was not identified in a Kor-
interaction alerts, 311 ean population, 211
Avery, A.J. see Magnus, D. Divanon, F., Hecquard, C. & Borel-Derlon, A. Experience
with use of recombinant activated factor VII, 133
Babalola, C.P., Iwheye, G.B. & Olaniyi, A.A. Effect of Donahue, S. see Reddy, P.
proguanil interaction on bioavailability of cloxacillin, Duffull, S. see Green, B.
461 Durand, A. see Monjanel-Mouterde, S.
Belal, F. see Walash, M.1.
Bertilsson, L. see Ding, B. Eastaugh, J. see Freemantle, N.
Bevanda, M. see Rosandic, M. Echizen, H. see Kadota, K.
BjOrnsdottir, I. & Hansen, E.H. Ethical dilemmas in anti- Egberts, T.C.G. see Bouvy, M.L.
biotic prescribing: analysis of everyday practice, 431 Eid, M. see Walash, M.I.
Boehm, B.-O. see Uhl, A.
Bonnier, P. see Monjanel-Mouterde, S. Fabb, W.E. see Chan, C.S.Y.
Borel-Derlon, A. see Divanon, F. Falisevac, V. see Rosandic, M.
Borenstein, M.R. see Tao, Q. Favetta, P. see Arsene, M.
Bouvy, M.L., Buurma, H. & Egberts, T.C.G. Laxative Favier, B. see Arsene, M.
prescribing in relation to opioid use and the influence Feret, B.M. see Reddy, P.
of pharmacy-based intervention, 107 Ferner, R.E. see Langford, N.J.
Bureau, J. see Arsene, M. Forrest, A. see Miyazawa, Y.
Burke, V. see Millar, J.A. Fowler, C. see Chow, A.T.
Buurma, H. see Bouvy, M.L. Freemantle, N. & Eastaugh, J. Using effectiveness studies
for prescribing research, part 1, 383
Chan, C.S.Y., Fabb, W.E. & Hazlett, C.B. Validation of an Freemantle, N. & Eastaugh, J. Using effectiveness studies
instrument to assess patient attitudes towards pre- for prescribing research, part 2, 469
scribing of pharmaceuticals by doctors:, 249 Fujii, A. see Kaneda, Y.
Chan, C.S.Y. see Wun, Y.T.
Chen, A. see Chow, A.T. Gaunt, M.J. see Maiorini, A.F.
Chiba, M. see Konishi, H. Ghayoumi, A. see Rouini, M.
Chien, S.-C., Rogge, M.C., Williams, R.R., Natarajan, J., Golding, S. see Ashworth, M.
Wong, F. & Chow, A.T. Absence of a pharmacokinetic Green, B., Duffull, S., Cottrell, N. & D’Emden, M. Myo-
interaction between digoxin and levofloxacin, 7 cardial infarction and type II diabetes — preferential
Chow, A.T., Chen, A., Lattime, H., Morgan, N., Wong, F., treatment for high risk patients?, 371
Fowler, C. & Williams, R.R. Penetration of levofloxacin
into skin tissue after oral administration of multiple Hadjaj, D. see Monjanel-Mouterde, S.
750 mg once-daily doses, 143 Hamada, M. see Hara, Y.
2002 Blackwell Science Ltd
476 AUTHOR INDEX
Hamed, A. see Ren, X.S. Konishi, H., Shimizu, S., Chiba, M., Minouchi, T., Koida,
Hamidi, M. see Rouini, M. M. & Yamaji, A. Predictive performance of serum
Hannaford, P.C. see Simpson, J.A. digoxin concentration in patients with congestive heart
Hansen, E.H. see Bj6rnsdottir, | failure by a hyperbolic model based on creatinine
Hansen, E.H. see Trap, B. clearance:, 257
Hanssens, Y., Deleu, D., Al Balushi, K., Al Hashar, A. Korac¢, B. see Rosandic¢, M.
& Al-Zakwani, I. Drug utilization pattern of anti- Kulicki, L. see Reddy, P.
epileptic drugs: a pharmacoepidemiologic study in
Oman, 357 Landray, M.J., Toescu, V. & Kendall, M.J. The cardio-
Hara, Y., Hamada, M., Shigematsu, Y., Ohtsuka, T. protective role of f-blockers in patients with diabetes
& Hiwada, K. Beneficial effect of replacing of angio- mellitus:, 233
tensin-converting enzyme inhibitor with angiotensin I] Langford, N.J., Martin, U., Ruprah, M. & Ferner, R.E.
antagonist for heart failure patients:, 267 Alternative venlafaxine kinetics in overdose, 465
Hazlett, C.B. see Chan, C.S.Y. angford, N.J. Aspirin and Reye’s syndrome: is the
Hecquard, C. see Divanon, F. response appropriate?, 157
Hefnawy, M. see Walash, M.I. arrivee-Elkins, C. see Oster Svedberg, K.
Hino, B. see Teshima, D. attime, H. see Chow, A.T.
Hirsch, G.M. see Thompson, A.E. ee, A. see Ren, XS.
Hiwada, K. see Hara, Y. 7. see Ren, X.S.
Hoffman, M. see Demoré, B .-B. see Park, H.-M.
Hoffman, M.A. see Demoreé, B. .-B. see Park, H.-M.
Hone, S. see Walshe, P. ejeune, C. see Monjanel-Mouterde, S.
Huang, Y.H. see Ren, X.S. i Wan Po, A. Digoxin-drug interactions study design
Hughes, L., Whittlesea, C. & Luscombe, D. Patients’ and generalizability, 5
knowledge and perceptions of the side-effects of OTC iao, S. see Tao, Q.
medication:, 243 lopis, P. see Sanchez-Alcaraz, A.
Joyd, D. see Ashworth, M.
Ibrahim, F. see Walash, M.I. Opez, E. see Sanchez-Alcaraz, A.
Ismailpour, A. see Rouini, M. uscombe, D. see Hughes, L.
Ito, Y. see Miyazawa, Y.
Itoh, Y. see Sendo, T. McKay, A.E. see Maiorini, A.F.
Itoh, Y. see Teshima, D. McKenzie, J. see Oster Svedberg, K.
Iwheye, G.B. see Babalola, C.P. Magnus, D., Rodgers, S. & Avery, A.J. GPs’ views on
computerized drug interaction alerts: questionnaire
Jacobsen, T.M. see Maiorini, A.F. survey, 377
Jayanarayan, K.G. & Dey, C.S. Microtubules: dynamic oS, Maiorini, A.F., Gaunt, M.J., Jacobsen, T.M., McKay,
drug interaction and drug resistance in Leishmania, 54 1i ~ 4 A.E., Waldman, L.D. & Raffa, R.B. Potential novel
Jones, B.W., Moore, D.J., Robinson, $.M. & Song, F. A targets for Alzheimer pharmacotherapy: I. Secretases,
systematic review of tegaserod for the treatment of 169
irritable bowel syndrome, 343 Majeed, A. see Ashworth, M.
Makino, K. see Sendo, T.
Kadota, K., Kamata, K., Kobayashi, Y., Kagaya, H., Shi- Mant, J. & Vessey, M. Using case-control studies for
mada, S., Yoshimoto-Furuie, K. & Echizen, H. Nomo- prescribing research, 67
gram for individualizing supplementary iron doses Martin, U. see Langford, N.].
during erythropoietin therapy in haemodialysis Merite, N. see Monjanel-Mouterde, S.
patients, 111 Mertz, A. see Uhl, A.
Kagaya, H. see Kadota, K. Millar, J.A. & Burke, V. Relationship between sample size
Kamalipour, A. see Akhondzadeh, S. and the definition of equivalence in non-inferiority
Kamata, K. see Kadota, K. drug studies, 329
Kamimura, H. see Miyazawa, Y. Miller, D.R. see Ren, X.S.
Kaneda, Y. & Fujii, A. Gynecomastia with sulpiride, 75 Minouchi, T. see Konishi, H.
Kang, S.-S. see Park, H.-M. Mirsepassi, G.-R. see Akhondzadeh, S.
Kazis, L.E. see Ren, X.S. Mishima, K. see Sendo, T.
Keller, F. see U hl, t Miyazawa, Y., Starkey, L.P., Forrest, A., Schentag, J.J.,
Kendall, M.J. & Nuttall, S.L. The heart protection study: Kamimura, H., Swarz, H. & Ito, Y. Effects of the con-
statins for all those at risk?, 1 comitant administration of tamsulosin (0-8 mg) on the
Kendall, M.J. see Landray, M.J. pharmacokinetic and safety profile of intravenous
Kephart, G.C. see Morningstar, B.A. digoxin (Lanoxin’) in normal healthy subjects a pla-
Kim, O.-N. see Park, H.-M cebo-controlled evaluation, 13
Kobayashi, Y. see Kadota, K. Moin, M. see Akhondzadeh, S.
Koida, M. see Konishi, H. Mojtahedzadeh, V. see Akhondzadeh, S.
2002 Blackwell Science Ltd, Journal of Clinical Pharmacy and Therapeutics, 27, 475-478
AUTHOR INDEX = 477
Mokbel, K. see Singh-Ranger, G. Rodriguez, I. see Sanchez-Alcaraz, A.
Monjanel-Mouterde, S., Lejeune, C., Ciccolini, J., Merite, Rogge, M.C. see Chien, S.-C.
Hadjaj, D., Bonnier, P., Piana, P. & Durand, Rosandi¢c, M., Pilas, Bevanda, M., FaliSevac, V. &
Bayesian population model of methotrexate to guide Korac, B. Quantification of Helicobacter |y yj lori resistance
dosage adjustments for folate rescue in patients with in functional and organic dyspepsia, 35 >3
breast cancer, 189 Ross-Degnan, D. see Wagner, A.K.
Moore, D.J. see Jones, B.W. Rouini, M., Hamidi, M., Ghayoumi, A. & Ismailpour, A.
Morgan, N. see Chow, A.T. Relationship of serum ACE inhibition to oral dose of
Morningstar, B.A., Sketris, I.S., Kephart, G.C. & Sclar, enalapril in normotensive oe 121
D.A. Variation in pharmacy prescription refill adher- Routledge, H.C., Chowdhary, S. & Townend, J.N. Heart
ence measures by type of oral eH td Siena rate \ rare —a See target?, 85
drug therapy in seniors in Nova Scotia, Canada,2 Rowley, H.s ¢ Walshe, P.
Ruprah, M. see Langford, N_J.
Natarajan, J. see Chien, S.-C.
Nguyen, ~ A. see Olsson, E. Sanchez-Alcaraz, A., Quintana, M*.B., Lopez, E., Rodri-
Nuttall, S ee Kendall, M.]. guez, I. & Llopis, P. Effect of vigabatrin on the phar-
—— of ~~ 427
O’Kane, C.J.A. see Whitefield, M. Sandberg, M. see Xie, H.-J.
Ohtsuka, T. see Hara, Y. Schentag, J.J. see Miyazawa, Y.
Oishi, R. see Sendo, T. Schock Citver, A., Shields, A.M., Ciaccia, L.M., Schu-
Oishi, R. see Teshima, D. lingkamp, R.J. & Raffa, R.B. Indirect Serer of
Olaniyi, A.A. see re Crs dopamine D2 receptors as potential pharmacotherapy
Olsson, E., Tuyet, L.T.N., Nguyen, H.A. & Stalsby for schizophrenia III. Retinoids, 161
Lundborg, C. Health professionals’ and consumers’ Schulingkamp, R.J. see Schock Citver, A.
views on the role of the pharmacy personnel and the Sclar, D.A. see Morningstar, B.A.
pharmacy service in Hanoi, Vietnam — a qualitative Sendo, T., Teshima, D., Makino, K., Mishima, K., Itoh,Y
_ study:, 273 & Oishi, R. Application of dynamic laser ona to
Oster Svedberg, K., McKenzie, J. & Larrivee-Elkins, C. the quality control of injectable drugs polymer for-
Compatibility of ropivacaine with morphine, sufenta- mation in ampicillin solution, 79
nil, fentanyl, or clonidine, 39 Shields, A.M. see Schock Citver, A.
Shigematsu, Y. see Hara, Y
Park, H.-M., Kang, S.-S., Lee, Y.-B., Shin, D.-J., Kim, O.- Shimada, S. see Kadota, K.
N., Lee, S.-B. & Yim, D.-S. Population pharmaco- Shimizu, S. see Konishi, H
kinetics of intravenous valproic acid in Korean Shin, D.-]. see Park, H.-M.
patients, 419 Simpson, J.A. & Hannaford, P.C. The contribution of
Pearson, G.a s see Thompson, A.E. cohort studies to prescribing research, 151
Perrin, A. see Demoré, B. Spe anes G. & Mokbel, K. Current concepts in
Piana, P. see Monjanel-Mouterde, S. cyclooxygenase inhibition in breast cancer, 321
Pilas, V. see Rosandic, M. Sketris, IS.s ee Morningstar, B.A.
Song, F. see Jones,B .W.
Quercia, R.A. see Reddy, P. Soumerai, S.B.s ee Wagner, A.K.
Quintana, M*.B. see Sanchez-Alcaraz, A. Stalsby andes C. see Olsson, E.
Starkey, L.P. see Miyazawa, Y.
Raffa, R.B. see Maiorini, A.F. Stone, D.J. see Tao, Q.
Raffa, R.B. see Schock Citver, A. Swarz, H. see Miyazawa, Y.
Raffa, R.B. see Tao, Q.
Ramesh, M. & Roberts, G. Use of night-time benzodia- Tao, Q., Stone, D.J., Borenstein, M.R., Codd, E.E., Coogan,
zepines in an elderly inpatient population, 93 T.P., Desai-Krieger, D., Liao, S. & Raffa, R.B. Differ-
Rane, A. see Xie, H.-J. ential tramadol and O-desmethy! metabolite levels in
Reddy, P., Feret, B.M., Kulicki, L., Donahue, S. & Quer- brain vs. plasma of mice and rats administered tra-
cia, R.A. Cost analysis of fentanyl and remifentanil in madol hydrochloride orally, 99
coronary artery bypass graft surgery without cardio- Teshima, D., Hino, Itoh, Y. & Oishi, R. Simple and
pulmonary bypass, 127 simultaneous determination of sulphapyridine and
Ren, X.S., Kazis, L.E., Lee, A., Zhang, H. & Miller, D.R. acetylsulphapyridine in human serum by column-
Identifying patient and physician characteristics that switching high-performance liquid chromatography,
affect compliance with antihypertensive medications, 403
47 Teshima, D. see Sendo, T.
Ren, X.S., Kazis, L.E., Lee, A.F., Hamed, A., Huang, Y.H., Thompson, Hirsch, G.M. & Pearson, G.J. Assess-
Cunningham, F. & Miller, D.R. Patient characteristics ment of new onset postcoronary artery bypass surgery
and prescription patterns of atypical antipsychotics atrial fibrillation current practice pattern review and
among patients with schizophrenia, 441 the ee of treatment guidelines, 21
Roberts, G. see Ramesh, M. Timon, C. see Walshe, P.
Robinson, S.M. see Jones, B.W. Toescu, Vv.s ee Landray, M.].
Rodgers, S. see Magnus, D. Townend, J.N. see Routledge, H.C.
2002 Blackwell Science Ltd, Journalo f Clinical Pharmacy and Therapeutics, 27, 475-478
478 AUTHOR INDEX
Trap, B. & Hansen, E.H. Treatment of upper respiratory Whitefield, M., O’Kane, C.J.A. & Anderson, S. Com-
tract infections - a comparative study of dispensing parative efficacy of a proprietary topical ibuprofen gel
and non-dispensing doctors:, 289 and oral ibuprofen in acute soft tissue injuries: a ran-
Tuyet, L.T.N. see Olsson, E. domized, double-blind study, 409
Whittlesea, C. see Hughes, L.
Uhl, A., Czock, D., Boehm, B.-O., Zellner, D., Mertz, A. & Williams, R.R. see Chien, S.-C.
Keller, F. Pharmacokinetics and pharmacodynamics of Williams, R.R. see Chow, A.T.
methylprednisolone after one bolus dose compared Wong, F. see Chien, S.-C.
with two dose fractions:, 281 Wong, F. see Chow, A.T.
Wun, Y.T., Chan, C.S.Y. & Dickinson, J.A. Determinants
Vessey, M. see Mant, J. of physicians’ attitude towards prescribing, 57
Vigneron, J. see Demore, B.
Xie, H.-J., Yasar, U., Sandberg, M. & Rane, A. Paeoniae
Wagner, A.K., Soumerai, $.B., Zhang, F. & Ross-Degnan, Radix, a traditional Chinese medicine, and CYP2C9
D. Segmented regression analysis of interrupted time activity, 229
series studies in medication use research:, 299
Wahlestedt, C. see Ding, B. Yamaji, A. see Konishi, H.
Walash, M.L., Belal, F., Ibrahim, F., Hefnawy, M. & Eid, Yasar, U. see Xie, H.-J.
M. Voltammetric determination of nitrosocimetidine in Yim, D.-S. see Park, H.-M.
simulated gastric juice, 365 Yoshimoto-Furuie, K. see Kadota, K.
Waldman, L.D. see Maiorini, A.F.
Walshe, P., Rowley, H., Hone, S. & Timon, C. Co-phe- Zellner, D. see Uhl, A.
nylcaine as an alternative to Brompton’s solution in Zhang, F. see Wagner, A.K.
rigid nasendoscopy: a pilot study, 185 Zhang, H. see Ren, X.S.
Whelan, A.M. Development of a Canadian family med-
icine pharmacy practice experience programme, 335
2002 Blackwell Science Ltd, Journal of Clinical Pharmacy and Therapeutics, 27, 475-478
Journal of Clinical Pharmacy and Therapeutics (2002) 27, 479-480
KEYWORD INDEX
ACE inhibitors, 85 Complicated skin infections, 143 Heart rate variability, 85
Acetaminophen, 391 Complicated skin-structure infec- Helicobacter pylori, 359.3
Acetylsulphapyridine, 403 tions, 143 Herbal supplements, 391
Active metabolite, 99 Computers, 377 Hierarchical design, 469
Adverse drug interactions, 391 Congestive heart failure, 257 Hormone replacement therapy, 67
Adverse drug reactions, 243 Content analysis, 273 HPLC, 139
Adverse effects, 403 Controlled trial, 221 HTF 919, 343
Alzheimer’s disease, 169 Co-phenylcaine, 185 Hyperbolic prediction model, 257
Ampicillin sodium, 79 Coronary artery bypass, 21 Hypertension, 47
Amyloid precursor protein, 169 Coronary heart disease, 233
Amyloid /-peptide, 169 Costs, 127 Ibuprofen, 409
Anaesthesia, 185 Creatinine clearance, 257 Iceland, 431
Analgesic drugs, 391 Cyclooxygenase-1 (COX-1), 321 Immunosuppression, 281
Angiotensin converting enzyme Cyclooxygenase-2 (COX-2), 321 Implementation, 383
activity, 121 Cyclooxyge-nase inhibitors, 321 Implementation study, 469
Angiotensin converting enzyme CYP2C9; 229 Infection, 353
inhibitors, 121 CYP2D6, 465 Initiation, 441
Angiotensin II receptor antagonist, Insulin, 371
267 Degradation, 205 Interactions, 427
Angiotensin-converting enzyme Diabetes, 213 Interrupted time series design, 299
inhibitor, 267 Diabetes mellitus, 233, 371 Intervention, 107
Antibiotic resistance, 353 Diazoxide, 453 Iron supplement nomogram, 111
Antibiotic use, 289 Diethylhexyl phthalate (DEHP), 139 Irritable bowel syndrome, 3435
Antibiotics, 431 Digoxin, 7, 13
Anti-epileptic drugs, 357 Dilated cardiomyopathy, 267 Knowledge, 243
Anti-hypertensive drugs, 121 Dispensing doctors, 289 Korean, 211
Antihypertensive medications, 47 Dosage, 289
Antimalarial, 461 Dose-effect relationship, 121 Laxatives, 107
Antimicrotubule agents, 313 Dose-response, 281 Leishmania, 313
Assay, 79 Dosing, 281 Levofloxacin, 7, 143
Atrial fibrillation, 21 Drug information, 335 Longitudinal analysis, 299
Attitude, 57 Drug interaction alerts, 377 Losartan, 229
Atypical antipsychotics, 441 Drug resistance, 313
Autonomic nervous system, 85 Drug utilization, 357 Medication adherence, 213
Drug-drug interaction, 461 Medication use research, 299
Baroreflex sensitivity, 85 Dyspepsia, 353 Metabolism, 465
Bayesian estimation, 189 Methotrexate, 189
Benzodiazepines, 93 Elderly patients, 93 Metronidazole, 353
Beta-blockers, 85 Enalapril, 121 Microtubules, 313
Bioavailability, 461 Epilepsy, 357 Mixed effect modelling, 419
f-blocker, 233, 267 Estradiol, 75 Mononitrosocimetidine (MNCM),
Blood glucose, 371 Etoposide, 139 365
Brain, 99 Myocardial infarction, 371
Breast cancer, 321 Family medicine, 335
Family practice, 377 Natriuretic peptides, 267
Carbamazepine, 427 Fentanyl, 127 Neuropeptide Y, 211
Cardiac surgery, 127 Folinic acid rescue, 189 Nitrosocimetidine (NCM), 365
Cardioprotection, 233 Functional, 353 Non-inferiority, 329
Case-control studies, 67 Non-steroidal anti-inflammatory
Ceftazidime, 205 Gas chromatography, 99 drugs, 409
Cimetidine, 365 General family practice, 249 Nose, 185
Clinical practice, 383 General practice, 377, 431 NSAIDs, 321, 391
Clinical trials, 329 Glass, 205
Cloxacillin, 461 Gonadotropins, 75 Obligations, 431
Cocaine, 185 Gynecomastia, 75 Opioids, 107, 391
Cohort studies, 151 Oral, 409
Column-switching, 403 Haemodialysis, 111 Oral antihyperglycaemic drugs, 213
Compliance, 47 Health policy evaluation, 299 Organic, 353
© 2002 Blackwell Science Ltd
480 KEYWORD INDEX
OTC medicines, 243 Prescribing indicators, 197 Side effects, 243
Overdose, 465 Prescribing information systems, 1, Simulated gastric juice (SGJ), 365
5, 7, 47, 57, 75 Single nucleotide polymorphism,
Paeoniae Radix, 229 Prescribing research, 151 211
Patient and physician character- Prescription, 57 Sleep, 93
istics, 47 Prescription behaviour, 249 Soft tissue injury, 409
Patient attitude, 249 Prescription patterns, 441 Sorption, 205
Patient characteristics, 441 Presenilin, 169 Stability, 79
Pharmacist, 107 Primary care groups, 197 Statistical analysis plan, 469
Pharmacodynamics, 281 Primary care, 57, 221 Statistical testing, 329
Pharmacoepidemiology, 357 Prioritization, 431 Study design, 469
Pharmacokinetic interaction, 13 Proguanil, 461 Submicron particle analysis, 79
Pharmacokinetics, 7, 143, 189, 419, Prolactin, 75 Sudden death, 85, 233
465 Pyridine, 205 Sulphapyridine, 403
Pharmaco-therapy, 357 Sulpiride, 75
Pharmacy, 273 Qualitative, 273 Switching, 441
Pharmacy practice experience pro- Qualitative methods, 431 Systematic review, 343
gramme, 335 Quality assurance, 21
Pharmacy practice research, 107 Quasi-experimental design, 299 Tamsulosin, 13
Pharmacy services, 335 Questionnaire survey, 377 Tegaserod, 343
Phenomenography, 273 Questionnaire validation, 249 Temazepam, 93
Phenytoin, 229 Testosterone, 75
Placebo-controlled study, 13 Randomized controlled trials, 383 Therapeutic equivalence, 329
Plasma, 99 RAR, 161 Thoracic surgery, 21
Plasma concentrations, 427 Remifentanil, 127 Thromboembolism, 67
Polymer formation, 79 Respiratory infections, 289 Topical, 409
Polypropylene, 205 Retinoid receptors, 161 Tramadol, 99
Polyvinyl chloride (PVC) bags, 139 Retinoids, 161 Treatment guidelines, 21
Polyvinyl chloride, 205 r-HuEPO, 111
Population, 419 Role, 273 Valproic acid, 419
Population-based study, 213 RXR, 161 Venlafaxine, 465
Posology, 281 Vigabatrine, 427
Potassium channels, 453 Safety, 13 Voltammetry, 365
Practice guidelines, 21 Schizophrenia, 161, 441, 453
Prescribing, 289 Secretase, 169
Prescribing adviser, 221 Segmented regression analysis, 299
Prescribing change, 221 Serum digoxin concentration, 257
© 2002 Blackwell Science Ltd, Journal of Clinical Pharmacy and T herapeutics, 27, 479-480